Erik C. Emerson
CIK: 0001710496
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
APUS
Apimeds Pharmaceuticals US, Inc.
DirectorOfficer
Discretionary Trading P&L
Holdings
About Emerson Erik C.
Emerson Erik C. (SEC CIK 0001710496) files insider reports with the SEC as Chief Executive Officer of Apimeds Pharmaceuticals US, Inc. (APUS).
Signal8 holds 3 ownership filings by Emerson Erik C. (1 Form 3, 2 Form 4), filed between May 8, 2025 and Oct 17, 2025. Those filings report 2 transactions, from May 16, 2025 to Oct 15, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Emerson Erik C.'s filings is in HOPEWELL, NJ.
Recent filings by Emerson Erik C.
Other insiders filing for Apimeds Pharmaceuticals US, Inc. (APUS)
- Sherb Eric Michael, Chief Financial Officer
- Menon Vin, Co-Chief Executive Officer
- Inscobee Inc., 10% Owner
- Weintraub Bennett, Director
- Yoon Hankil, Director
- Koo Jakap, Director